Diabetes mellitus type 2 (T2DM) is characterized by bifactorial pathogenesis, impaired insulin secretion and increased insulin resistance; whether insulin resistance or insulin deficiency is the primary disorder have been intensively debated. Patients with T2DM are at risk of developing long term complications' including microvascular, macrovascular and neuropathic disease. The early intervention in T2DM treatment should include patient education, dietary counselling and changes in life style. Oral drug therapies include sulphonylurea derivatives, metformin (which is the treatment of choice in obese patients), combination of two classes, alfa-glucosidase inhibitors such as acarbose, used mainly to reduce post-prandial blood glucose peaks. Insulin may be required when oral hypoglycaemic drugs failed to control high blood levels. Hypertension, hyperlipidemia, coronary heart disease and obesity require particular care in diabetic patients. New drugs as alanine derivatives (repaglinide, nateglinide) and thiazolidinediones (rosiglitazone, pioglitazone) could have increasing importance in the early future.
|Number of pages||6|
|Publication status||Published - 2000|
ASJC Scopus subject areas